罗格列酮治疗伴有代谢综合征2型糖尿病的疗效观察

Clinical study of Rosiglitazone(Avandia)in treating type 2 diabetes mellitus with Metabolic Syndrome.

目的对罗格列酮(文迪雅)单用或与口服降糖药合用治疗伴有代谢综合征2型糖尿病临床疗效及安全性进行观察。方法 68例伴有代谢综合征2型糖尿病患者进行为期12周的文迪雅治疗的观察。结果与基线期相比,文迪雅治疗12周后患者空腹血糖(FBG)、糖化血红蛋白(HbA_1c)、空腹胰岛素(FINS)水平均有显著下降,胰岛素抵抗指数(HOMA 指数)下降,甘油三酯(TG)下降,收缩压和舒张压降低。结论文迪雅是胰岛素增敏剂,有明显的降低2型糖尿病患者 FBG、FINS、HbA_1c,减少胰岛素抵抗的效果,有降压、调脂、保护胰岛功能,是治疗伴有代谢综合征2型糖尿病有效而安全的理想口服降糖药物。

Objective To observe the clinical efficieney and safety of Rosiglitazone(Avandia)Monotherapy or combi- nation with oral hypoglycemic agents in treating type 2 diabetes mellitus with Metabolic syndrome.Methods 68 type 2 diabetic patients with Metabolic syndrome were assigned to receive Avandia treatment at doses of 4mg for 12 weeks.Re,. sults Avandia used alone or in combination with oral hypoglycemic agents significantly reduced fasting plasma glucose (FBG)and fasting plasma insulin(FINS).Mean glycosylated hemoglobin values were significantly deereaseel.Home- ostasis model assessmen indicate that RSG reduced insulin resistance.There were statistically significiant decrease in systolic blood pressure(SBP)and diastolic blood pressure(DBP).No significant side-effects on kidney and liver function were found.Conclusion Avandia is an insulin sensitizer that is effective and safe on the treatment of Type 2 Diabetes with Metabolic syndrome by decreasing blood glucose and blood lipid,improving insulin resistance,and main- taining the function of pancreatic island cells.